Notice of Capital Markets Day
Instem plc
("Instem" or "the Company" or "the Group")
Notice of Capital Markets Day
Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that it will be hosting a virtual Capital Markets Day for retail investors on Thursday 01 July 2021.
During the event, management will provide greater insight into the business, its ongoing acquisition strategy and its growth potential. The event will include presentations detailing developments in each of the Company's business lines as well as the wider market opportunity. There will be opportunities for attendees to ask questions during the webcast.
The session, lasting 2 hours, will be hosted between 14:00 to 16:00 BST welcoming retail investors.
If you are interested in attending or have any questions relating to the Capital Markets Day, please contact Walbrook via instem@walbrookpr.com .
Institutional Investor Event
The Company will also be hosting a separate virtual Capital Markets Day at the same times on Wednesday 30 June 2021 for Institutional investors. If you are interested in attending please contact kimberley.young@n1singer.com .
For further information, please contact:
|
Instem plc |
Via Walbrook |
|
Phil Reason, CEO |
|
|
Nigel Goldsmith, CFO |
|
|
|
|
|
N+1 Singer (Nominated Adviser & Broker) |
+44 (0) 20 7496 3000 |
|
Peter Steel Alex Bond Rachel Hayes |
|
|
|
|
|
Walbrook Financial PR |
+44 (0) 20 7933 8780 |
|
Tom Cooper |
|
|
Nick Rome Nicholas Johnson |
|
About Instem
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.
Instem solutions are in use by over 600 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.
To learn more about Instem solutions and its mission, please visit www.instem.com
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 hour ago Molten Ventures
- 1 hour ago Touchstone Exploration Inc NPV (DI)
- 1 hour ago Team Internet Group plc
- 1 hour ago Ondo Insurtech
- 1 hour ago Wilmington